Hydroxypinacolone retinoate
Based on 1 Customer Validation
Hydroxypinacolone retinoate (HPR) is a direct-binding agonist of retinoic acid receptor (RAR). Hydroxypinacolone retinoate has low irritation and high stability; when formulated into nanoparticles, its transdermal efficiency is enhanced, allowing it to penetrate deep into the dermis and achieve sustained release. When used in combination with Retinyl propionate, hydroxypinacolone retinoate promotes fibroblast proliferation and upregulates the gene expression of type IV collagen, CRBP-I and RARB. Hydroxypinacolone retinoate can be used in research related to skin wrinkles and skin aging.
For research use only. We do not sell to patients.
- Purity : 99.33%
- CAS No.: 893412-73-2
- Formula: C26H38O3
- Molecular Weight:398.58
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Gravi-A nanoparticles containing ydroxypinacolone retinoate (3.0 wt%; 0.5-4 h) achieve four times higher transdermal efficiency and deeper skin penetration in porcine skin compared to free HPR, with 52.90 μg/cm2 intradermal retention after 4 h[1].
Gravi-A nanoparticles containing ydroxypinacolone retinoate (0.006-0.01% (v/v); 72 h) promote type I collagen synthesis in human dermal fibroblasts, with upregulation rates of 226%, 194%, and 217% at concentrations of 0.01%, 0.008%, and 0.006% (v/v) respectively[1].
Hydroxypinacolone retinoate (5 μg/mL; 24-72 h) cotreated with 9 μg/mL retinyl propionate significantly increases human foreskin fibroblast (HFF-1) cell viability by ~40% at 24 h, with negligible toxicity across 24, 48, and 72 h timepoints[2].
Hydroxypinacolone retinoate (5 μg/mL; 24-72 h) cotreated with 9 μg/mL retinyl propionate synergistically enhances mRNA expression of Col I, Col III, Col IV, CRBP I, and RARB across 24, 48, and 72 h, with the strongest synergy observed for CRBP I (up to 33-fold at 72 h)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human dermal fibroblasts
-
Concentration:0.0078-2% (v/v)
-
Incubation Time:24 h
-
Result:Exhibited dose-dependent cytotoxicity, with the highest relative cell growth rate of 114.69% at 0.0078% (v/v).
Had an IC50 value of 8.933% (v/v), which was significantly higher than the IC50 of free HPR + RP (1.308% v/v).
-
Cell Line:Human dermal fibroblasts
-
Concentration:0.006-0.01% (v/v)
-
Incubation Time:72 h
-
Result:Upregulated human type I collagen synthesis by 226% at 0.01% (v/v) compared to the negative control (p < 0.05).
Upregulated human type I collagen synthesis by 194% at 0.008% (v/v) compared to the negative control (p < 0.05).
Upregulated human type I collagen synthesis by 217% at 0.006% (v/v) compared to the negative control (p < 0.05).
Showed higher upregulation rates than free HPR + RP.
-
Cell Line:human foreskin fibroblast (HFF-1) cells
-
Concentration:5 μg/mL (cotreated with 9 μg/mL retinyl propionate)
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Increased HFF-1 cell viability by approximately 40% after 24 h compared to control and individual treatment groups.
Exhibited negligible toxicity across all timepoints.
Slightly enhanced cell viability at 72 h compared to control.
-
Cell Line:human foreskin fibroblast (HFF-1) cells
-
Concentration:5 μg/mL (cotreated with 9 μg/mL retinyl propionate)
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Increased Col IV mRNA expression by more than 2.5-fold, CRBP I expression by approximately 11-fold, and RARB expression by roughly 4-fold at 24 h.
Enhanced Col I mRNA expression by more than 4-fold, Col III expression by 73.0%, Col IV expression by more than 2.5-fold, CRBP I expression by approximately 30-fold, and RARB expression by roughly 4-fold at 48 h.
Boosted Col I mRNA expression by more than 3.5-fold, Col IV expression by more than 2.5-fold, CRBP I expression by approximately 33-fold, and RARB expression by roughly 5.7-fold at 72 h.
In Vivo
Gravi-A nanoparticles containing 3.0 wt% HPR (3.0 wt%; topical to CAM; single dose) causes slight chick embryo chorioallantoic membran (CAM) vessel bleeding only at full concentration, with an irritation threshold of 94.51% in SPF white Laihang chicken embryos[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:New Zealand rabbits (1.5-2.0 kg)[1]
-
Dosage:3.0 wt%
-
Administration:topical; daily; 14 days
-
Result:Recorded an average daily skin irritation score per animal of 0.68, classified as mild irritation.
-
Animal Model:SPF white Laihang chicken embryos[1]
-
Dosage:3.0 wt% (50% sample concentration; 80% sample concentration; 100% sample concentration)
-
Administration:topical to CAM; single dose
-
Result:Showed normal CAM vessels with no significant changes at 50% and 80% sample concentrations after 30 minutes.
Observed slight vessel bleeding at 100% sample concentration.
Calculated an irritation threshold (IEW RC50) of 94.51%.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 893412-73-2
-
Appearance Solid
-
Molecular Weight 398.58
-
Formula C26H38O3
-
Color White to yellow
-
SMILES
CC(C)(C)C(COC(/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)=O)=O
-
Synonyms
HPR
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 12.5 mg/mL (31.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 12.5 mg/mL (31.36 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.14 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 2.5089 mL | 12.5445 mL | 25.0891 mL | 62.7227 mL |
| 5 mM | 0.5018 mL | 2.5089 mL | 5.0178 mL | 12.5445 mL | |
| 10 mM | 0.2509 mL | 1.2545 mL | 2.5089 mL | 6.2723 mL | |
| 15 mM | 0.1673 mL | 0.8363 mL | 1.6726 mL | 4.1815 mL | |
| 20 mM | 0.1254 mL | 0.6272 mL | 1.2545 mL | 3.1361 mL | |
| 25 mM | 0.1004 mL | 0.5018 mL | 1.0036 mL | 2.5089 mL | |
| 30 mM | 0.0836 mL | 0.4182 mL | 0.8363 mL | 2.0908 mL |
Hydroxypinacolone retinoate Related Classifications
HY-W442049 Related Classifications
Powered by Bioz